Endogene Ltd. is an Australian-based medical device technology company with a vision to be a leading and long-term developer and innovator of novel treatments, medical devices, and management solutions, incubating and nurturing technologies from invention through to commercialisation in global markets. Endogene current focus is on its Parascope self-propel;ling single-use gastrointestinal endoscope platform, a potentially "disruptive" technology capbale of having a major impact on existing products and treatment modalities in major markets. The Parascope system incorporates Endogene's proprietary Fluid Kinetic Propulsion technology, which enables unprecedented, rapid and reliable access to the entire gastrointestinal tract. This technology eliminates the need to "push" the endoscope and facilitates the manufacture of cost-competitive, single-use, all-sterile, recyclable endoscopes which, eliminate the risk of cross-contamination associated with reusable endoscopes. Single-use gastrointestinal endoscopes are the future, creating a multi-billion dollar global market whilst eliminating cross-contamination, infection and deaths caused by reusable endoscopes. For further information, visit www.endogene.com.au
Looking for a particular Endogene Ltd. employee's phone or email?
The Endogene Ltd. annual revenue was $2 million in 2026.
Anthony Switzer is the CEO of Endogene Ltd..
3 people are employed at Endogene Ltd..
Endogene Ltd. is based in Brighton, Victoria.
The NAICS codes for Endogene Ltd. are [339, 33].
The SIC codes for Endogene Ltd. are [38, 384].